AR065581A1 - Mejoras en composiciones medicinales o relativas a las mismas - Google Patents

Mejoras en composiciones medicinales o relativas a las mismas

Info

Publication number
AR065581A1
AR065581A1 ARP080100882A ARP080100882A AR065581A1 AR 065581 A1 AR065581 A1 AR 065581A1 AR P080100882 A ARP080100882 A AR P080100882A AR P080100882 A ARP080100882 A AR P080100882A AR 065581 A1 AR065581 A1 AR 065581A1
Authority
AR
Argentina
Prior art keywords
same
medicinal compositions
composition
naloxone
buprenorphine
Prior art date
Application number
ARP080100882A
Other languages
English (en)
Inventor
Christopher Bourne Chapleo
Neil Hyde
Original Assignee
Reckitt Benckiser Healthcare
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reckitt Benckiser Healthcare filed Critical Reckitt Benckiser Healthcare
Publication of AR065581A1 publication Critical patent/AR065581A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una composicion para el tratamiento del dolor en pacientes humanos, en donde dicha composicion comprende buprenorfina a naloxona en una relacion en peso entre 2,1:1 y 8:1, siendo la cantidad de buprenorfina naloxona adecuada para proveer analgesia,y estando la composicion en una forma de dosificacion transdérmica o transmucosa. Un método y uso asociados.
ARP080100882A 2007-03-01 2008-02-29 Mejoras en composiciones medicinales o relativas a las mismas AR065581A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0703967A GB2447015A (en) 2007-03-01 2007-03-01 Analgesic composition comprising a specific ratio of buprenorphine and naltrexone

Publications (1)

Publication Number Publication Date
AR065581A1 true AR065581A1 (es) 2009-06-17

Family

ID=37965734

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080100882A AR065581A1 (es) 2007-03-01 2008-02-29 Mejoras en composiciones medicinales o relativas a las mismas

Country Status (16)

Country Link
US (1) US20100168147A1 (es)
EP (1) EP2114453A1 (es)
JP (1) JP2010520185A (es)
KR (1) KR20090115863A (es)
CN (2) CN102670610A (es)
AR (1) AR065581A1 (es)
AU (1) AU2008220573A1 (es)
BR (1) BRPI0807905A2 (es)
CA (1) CA2678675A1 (es)
CL (1) CL2008000610A1 (es)
GB (1) GB2447015A (es)
MX (1) MX2009009133A (es)
PE (1) PE20081874A1 (es)
TW (1) TW200836738A (es)
WO (1) WO2008104737A1 (es)
ZA (1) ZA200905691B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2054031T3 (en) 2006-07-21 2016-05-17 Biodelivery Sciences Int Inc Transmucosal delivery devices with improved uptake
US20110189259A1 (en) * 2008-06-23 2011-08-04 Biodelivery Sciences International, Inc. Multidirectional mucosal delivery devices and methods of use
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
KR101944367B1 (ko) 2011-08-18 2019-01-31 바이오딜리버리 사이언시스 인터내셔널 인코포레이티드 부프레노르핀 운반용 약물남용 억제 점막 부착 장치
PL2915525T3 (pl) * 2011-09-19 2022-01-17 Orexo Ab Tabletki podjęzykowe niepodatne na nadużywanie zawierające buprenorfinę i nalokson
US9901539B2 (en) 2011-12-21 2018-02-27 Biodelivery Sciences International, Inc. Transmucosal drug delivery devices for use in chronic pain relief
US20140275148A1 (en) * 2013-03-15 2014-09-18 Novus Pharma LLC Orally administrable, self-supporting dissolving film dosage forms
CA2875384A1 (en) 2013-12-20 2015-06-20 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
US9561177B2 (en) 2014-03-14 2017-02-07 Adapt Pharma Limited Nasal drug products and methods of their use
US10085937B2 (en) 2014-03-14 2018-10-02 Adapt Pharma Limited Nasal drug products and methods of their use
US9480644B2 (en) 2014-03-14 2016-11-01 Opiant Pharmaceuticals, Inc. Nasal drug products and methods of their use
CN110755372A (zh) 2014-03-14 2020-02-07 欧皮安特制药有限公司 适于经鼻递送药物产品、用于鼻内给予的药用组合物及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4457933A (en) * 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
GB8332556D0 (en) * 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
EP1041988A4 (en) * 1997-12-22 2002-03-13 Euro Celtique Sa METHOD FOR PREVENTING ABUSE OF OPIOID DOSES FORMS
AR031682A1 (es) * 1999-11-19 2003-10-01 Reckitt Benckiser Helthcare Uk Composiciones farmaceuticas
US20050191340A1 (en) * 2002-08-09 2005-09-01 Gruenenthal Gmbh Opioid-receptor antagonists in transdermal systems having buprenorphine
AU2003283055A1 (en) * 2002-08-09 2004-02-25 Grunenthal Gmbh Opioid-receptor antagonists in transdermal systems having buprenorphine
EP1584335A3 (en) * 2004-04-05 2006-02-22 Laboratorios Del Dr. Esteve, S.A. Active substance combination comprising a carbinol composition and an opioid
WO2008109779A2 (en) * 2007-03-07 2008-09-12 The Johns Hopkins University Use of follistatin-like related gene (flrg) to increase muscle mass

Also Published As

Publication number Publication date
EP2114453A1 (en) 2009-11-11
PE20081874A1 (es) 2009-01-26
MX2009009133A (es) 2009-09-03
AU2008220573A1 (en) 2008-09-04
BRPI0807905A2 (pt) 2014-06-17
CA2678675A1 (en) 2008-09-04
CN101622013A (zh) 2010-01-06
TW200836738A (en) 2008-09-16
CN102670610A (zh) 2012-09-19
WO2008104737A1 (en) 2008-09-04
ZA200905691B (en) 2010-10-27
CL2008000610A1 (es) 2008-09-05
GB2447015A (en) 2008-09-03
JP2010520185A (ja) 2010-06-10
GB0703967D0 (en) 2007-04-11
KR20090115863A (ko) 2009-11-09
US20100168147A1 (en) 2010-07-01

Similar Documents

Publication Publication Date Title
AR065581A1 (es) Mejoras en composiciones medicinales o relativas a las mismas
CL2011002248A1 (es) Composicion farmaceutica oral de liberacion inmediata que comprende oxicodona y naloxona en una proporcion 2:1 en peso; uso de la composicion farmaceutica para tratar dolor intercurrente en paciente que sufren de dolor.
CL2012000313A1 (es) Composición de dosificación de película que comprende una matriz portadora, entre 2-16 mg de buprenorfina, entre 0,5-5 mg de naloxona y un tampón que proporciona un ph local entre 2-4; procedimiento de preparación; uso en el tratamiento de la dependencia de narcóticos en un usuario.
PE20090168A1 (es) Composiciones farmaceuticas de buprenorfina y naloxona
CL2011002858A1 (es) Uso de una composicion farmaceutica transmucosa oral que comprende dexmedetomidina y una sal farmaceuticamente aceptable y un excipiente farmaceuticamente aceptable para preparar un medicamento util para tratar o prevenir el dolor.
PE20081799A1 (es) Mejoras en composiciones medicinales o relativas a las mismas
MX2009002196A (es) Oblea de buprenorfina para terapia de sustitucion de farmacos.
BRPI0906181A2 (pt) "método para tratamento de uma disfunção hiperproliferativa, composição farmacêutica, uso de uma combinação terapêutica na fabricação de um medicamento para o tratamento de câncer, artigo de fabricação para tratamento de uma disfunção hiperproliferativa, método para determinação de compostos a serem usados em combinação para o tratamento de câncer e método para determinação de uma combinação terapêutica a ser usada para o tratamento de câncer"
DE602007007991D1 (de) Kleinvolumige, orale, transmukosale dosierungsformen mit sufentanil zur schmerzbehandlung
BRPI0418228A (pt) forma de dosagem, e, métodos de tratamento de dor e de episódios de dor incidente de cáncer, e de preparação de um tablete para administração bucal, gengival ou sublingual de fentanil
SV2009003098A (es) Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
ATE543491T1 (de) Kombinationspräparat enthaltend ibuprofen und paracetamol
CL2008002545A1 (es) Compuestos derivados de fenoxi-bencil-carbamoilo; composicion farmaceutica; procedimiento para preparar la composicion farmaceutica; y su uso en el tratamiento del dolor.
AR063782A1 (es) Parche y metodo transdermico para emesis
CL2009001841A1 (es) Uso de una composición de liberación sostenida de 4-aminopiridina para preparar un medicamento útil para tratar esclerosis multiple en un sujeto.
PE20090625A1 (es) Composicion farmaceutica que contiene buprenorfina y nalmefeno
CL2010000524A1 (es) Uso de una composición tópica que comprende 3,75% de imiquimod y un portador farmacéuticamente aceptable para preparar un medicamento útil para tratar verrugas genitales o perianales.
AR084093A1 (es) Metodo para tratar los atracones o la ingesta compulsiva de alimentos; uso de buproprion y naltrexona para preparar un medicamento para dichos metodos, y composicion farmaceutica
NZ719087A (en) Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
AR065139A1 (es) Medicamento para el tratamiento de la endometriosis
CL2010001577A1 (es) Uso de nifurtimox para preparar un medicamento util en el tratamiento de enfermedades causadas por giardias.
CL2008000965A1 (es) Composicion farmaceutica que comprende un agente antiinflamatorio no esteroideo y un analgesico opiaceo, y su uso para el tratamiento del dolor.
TW200611697A (en) Generally linear effervescent oral fentanyl dosage form and methods of administering
CL2008002465A1 (es) Composición farmacéutica anhidra tópica, que comprende derivados de niacina y un portador aceptable, su aplicacón permite un bienestar sexual mejorado.
AR047154A1 (es) Tratamiento del insomnio en pacientes humanos administrandoles una cantidad diaria de gaboxadol

Legal Events

Date Code Title Description
FA Abandonment or withdrawal